Hussman Strategic Advisors Inc. Increases Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Hussman Strategic Advisors Inc. increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 252,000 shares of the company’s stock after acquiring an additional 42,000 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Amneal Pharmaceuticals were worth $1,996,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals in the third quarter worth $37,000. Quest Partners LLC purchased a new stake in Amneal Pharmaceuticals in the third quarter worth $84,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Amneal Pharmaceuticals in the fourth quarter worth $81,000. Janney Montgomery Scott LLC purchased a new stake in Amneal Pharmaceuticals in the fourth quarter worth $121,000. Finally, Quadrature Capital Ltd purchased a new stake in Amneal Pharmaceuticals in the third quarter worth $169,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Up 0.8 %

AMRX opened at $7.85 on Thursday. The stock has a fifty day simple moving average of $8.04 and a two-hundred day simple moving average of $8.27. The company has a market cap of $2.43 billion, a price-to-earnings ratio of -11.54 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48.

Insider Activity

In other news, Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the transaction, the director now directly owns 2,031,476 shares in the company, valued at $16,272,122.76. This trade represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 160,000 shares of company stock worth $1,292,000 over the last three months. 26.56% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on AMRX shares. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Piper Sandler increased their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.